Decreased 5-Hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Orr, Brent A ^a   Haffner, Michael C ^b   Nelson, William G ^a,b,c   Yegnasubramanian, Srinivasan ^b   Eberhart, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; CANCER GRADING; CANCER PROGNOSIS; CELL TYPE; CHILD; COMPUTER MODEL; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FEMALE; FETUS; GENE EXPRESSION; GENE MUTATION; GENETIC REGULATION; GLIOBLASTOMA; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; IDH1 GENE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEURAL STEM CELL; NEWBORN; PHENOTYPE; PRESCHOOL CHILD; PROTEIN DEFICIENCY; PROTEIN LOCALIZATION; SCHOOL CHILD; STROMA; SURVIVAL TIME;

BRAIN; CELL DIFFERENTIATION; CYTOSINE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; NEURONS; STEM CELLS;

EID: 84864053192     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041036     Document Type: Article

References (52)

1. Reik W, (2007) Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447(7143): 425-432.
2. Jones PA, Baylin SB, (2007) The epigenomics of cancer. Cell 128(4): 683-692.
3. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, et al. (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929): 930-935.
4. Branco MR, Ficz G, Reik W, (2011) Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet 13(1): 7-13.
5. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, et al. (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2(8): 627-637.
6. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, et al. (2010) Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One 5(12): e15367.
7. Kriaucionis S, Heintz N, (2009) The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain. Science 324(5929): 929-930.
8. Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, et al. (2011) Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473(7347): 394-397.
9. Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, et al. (2011) Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 473(7347): 398-402.
10. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, et al. (2011) TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473(7347): 343-348.
11. He YF, Li BZ, Li Z, Liu P, Wang Y, et al. (2011) Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333(6047): 1303-1307.
12. Guo JU, Su Y, Zhong C, Ming GL, Song H, (2011) Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 145(3): 423-434.
13. Szulwach KE, Li X, Li Y, Song CX, Wu H, et al. (2011) 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 14(12): 1607-1616.
14. Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H, (2010) Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 38(19): e181.
15. Munzel M, Globisch D, Bruckl T, Wagner M, Welzmiller V, et al. (2010) Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl 49(31): 5375-5377.
16. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, et al. (2011) 5-hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 71(24): 7360-7365.
17. Xu W, Yang H, Liu Y, Yang Y, Wang P, et al. (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19(1): 17-30.
18. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897): 1807-1812.
19. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8): 765-773.
20. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324(5924): 261-265.
21. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2010) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465(7300): 966.
22. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5): 510-522.
23. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, et al. (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34): 4482-4490.
24. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, et al. (2010) The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 119(4): 487-494.
25. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6): 553-567.
26. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390): 479-83.
27. Capper D, Simon M, Langhans CD, Okun JG, Tonn JC, et al. (2011) 2-hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 131(3): 766-768.
28. Louis DN, (2007) WHO classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer. 309 p.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844-847.
30. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17(1): 98-110.
31. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, et al. (2010) Role of tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466(7310): 1129-1133.
32. Iqbal K, Jin SG, Pfeifer GP, Szabo PE, (2011) Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A 108(9): 3642-3647.
33. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6): 597-602.
34. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, et al. (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 118(4): 469-474.
35. Cancer Genome Atlas Research Network, (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216): 1061-1068.
36. Bhutani N, Burns DM, Blau HM, (2011) DNA demethylation dynamics. Cell 146(6): 866-872.
37. Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, et al. (2009) Rembrandt: Helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 7(2): 157-167.
38. Martin Caballero I, Hansen J, Leaford D, Pollard S, Hendrich BD, (2009) The methyl-CpG binding proteins Mecp2, Mbd2 and kaiso are dispensable for mouse embryogenesis, but play a redundant function in neural differentiation. PLoS One 4(1): e4315.
39. Zhou Z, Hong EJ, Cohen S, Zhao WN, Ho HY, et al. (2006) Brain-specific phosphorylation of MeCP2 regulates activity-dependent bdnf transcription, dendritic growth, and spine maturation. Neuron 52(2): 255-269.
40. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, et al. (1999) Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23(2): 185-188.
41. Yildirim O, Li R, Hung JH, Chen PB, Dong X, et al. (2011) Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147(7): 1498-1510.
42. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358(11): 1148-1159.
43. Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, et al. (2012) Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base" are associated with anaplasia in human brain tumours. Int J Cancer in press.
44. Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, et al. (2011) 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6(2): e16812.
45. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483(7390): 479-483.
46. Kim YH, Pierscianek D, Mittelbronn M, Vital A, Mariani L, et al. (2011) TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 64(10): 850-852.
47. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, et al. (2011) Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146(1): 67-79.
48. Wu H, D'Alessio AC, Ito S, Xia K, Wang Z, et al. (2011) Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473(7347): 389-393.
49. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, et al. (2008) Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68(19): 8094-8103.
50. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, et al. (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14(1): 123-129.
51. Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, et al. (2011) Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution. Ann Surg Oncol 18(10): 2937-2945.
52. Booth MJ, Branco MR, Ficz G, Oxley D, Krueger F, et al. (2012) Quantitative sequencing of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution. Science 336(6083): 934-7.